Home
Welcome to the Swiss Peritoneal Cancer Group
The Swiss Peritoneal Cancer Group (SPCG) was founded in June 2013 and two years later the group was accepted as a workgroup of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC). The SPCG provides a platform for surgeons, gynecologists and medical oncologists engaged in peritoneal malignancies, cytoreduction and HIPEC.
Swiss Peritoneal Cancer Group
The aims and tasks of the SPCG are:
- One meeting per year
- General assembly during the congress of the Swiss Society for Surgery (Schweizerische Gesellschaft für Chirurgie, SGC) or during a congress of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC)
- Establishing a Swiss registry for cytoreduction/HIPEC
- Organization and realization of a regular congress on cytoreduction/HIPEC in Switzerland
- Promotion of research in the field of cytoreduction/HIPEC
We are proud to present to you the current list of responsibilities in the SPCG.
Michel Adamina
President
Martin Hübner
Vice-president
Kuno Lehmann
Secretary
Thomas Steffen
Board Member
Ralph Peterli
Board member SGVC
Beat Gloor
Board Member
Thibaud Köessler
Board Member
Fréderic Ris
Board member
Swiss Society of Visceral Surgery
The society aims to promote visceral surgery in cooperation with and within the Swiss Society of Surgery (Schweizerische Gesellschaft für Chirurgie, SGC). It deals primarily with health policy issues, professional policy aspects, problems and quality of education and training as well as certification requirements. The society represents the interests of visceral surgeons in professional organizations and in collective bargaining. The group collaborates with European professional societies with the same or similar interests and can join such societies as a member.
Upcoming events
September 3, 2021
Lausanne University Hospital (CHUV)
Symposium of the Swiss Peritoneal Cancer Group
Agora
Rue du Bugnon 25A
CH-1005 Lausanne
Programm hier downloaden
September 3, 2021
Lausanne University Hospital (CHUV)
General Assembly of the Swiss Peritoneal Cancer Group
Agora
Rue du Bugnon 25A
CH-1005 Lausanne
Programm hier downloaden
Swiss Publications
Michel Adamina, Maxime Warlaumont, Beat Gloor, Thibaud Köessler, Kuno Lehmann, Ralph Peterli, Frédéric Ris, Thomas Steffen, Antonia Digklia, Martin Hübner
Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis.
Solass, W, Sempoux, C, Carr, N J, Bibeau, F, Neureiter, D, Jager, T, Di Caterino, T, Brunel, C, Klieser, E, Fristrup, C W, Mortensen, M B, Detlefsen, S.
Histopathology, (2019) 74 (7):1014-24.doi:10.1111/his.13829 PMID:30687944
Systemic inflammatory response after hyperthermic intraperitoneal chemotherapy (HIPEC): The perfusion protocol matters!
Roth, L, Eshmuminov, D, Laminger, F, Koppitsch, C, Schneider, M, Graf, T R, Gupta, A, Kober, F, Roka, S, Gertsch, P, Lehmann, K.
Eur J Surg Oncol, (2019) doi: 10.1016/j.ejso.2019.03.036 PMID:30954352
Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.
Mertens, L S, Behrendt, M A, Mehta, A M, Stokkel, L, de Jong, J, Boot, H, Horenblas, S, van der Heijden, M S, Moonen, L M, Aalbers, A G J, Meinhardt, W, van Rhijn, B W G.
Eur J Surg Oncol, (2019) doi: 10.1016/j.ejso.2019.03.034 PMID:31003721
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
Arjona-Sanchez, A, Rodriguez-Ortiz, L, Baratti, D, Schneider, M A, Gutierrez-Calvo, A, Garcia-Fadrique, A, Tuynman, J B, Cascales-Campos, P A, Martin, V C, Morales, R, Salti, G I, Arteaga, X, Pacheco, D, Alonso-Gomez, J, Yalkin, O, Villarejo-Campos, P, Sanchez-Hidalgo, J M, Casado-Adam, A, Cosano-Alvarez, A, Rufian-Pena, S, Briceno, J.
Ann Surg Oncol, (2019) doi: 10.1245/s10434-019-07378-9 PMID:31111351
Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane) for peritoneal carcinomatosis – a phase I first-in-human study.
Van De Sande, L, Graversen, M, Hubner, M, Pocard, M, Reymond, M, Vaira, M, Cosyns, S, Willaert, W, Ceelen, W.
Pleura Peritoneum, (2018) 3 (2):20180112.doi:10.1515/pp-2018-0112 PMID:30911657
Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy.
Teixeira Farinha, H, Grass, F, Labgaa, I, Pache, B, Demartines, N, Hubner, M.
J Cancer, (2018) 9 (1):13-20.doi:10.7150/jca.21460 PMID:29290765
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO.
Oliver Goetze, T, Al-Batran, S E, Pabst, U, Reymond, M, Tempfer, C, Bechstein, W O, Bankstahl, U, Gockel, I, Konigsrainer, A, Kraus, T, Monig, S P, Rau, B, Schwarzbach, M, Piso, P.
Pleura Peritoneum, (2018) 3 (2):20180113.doi: 10.1515/pp-2018-0113 PMID:30911658
http://www.ncbi.nlm.nih.gov/pubmed/30911658
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the “Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)”, the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann, A M, Fink, D, Harter, P, Heinzelmann, V, Marth, C, Mueller, M, Reinthaller, A, Tamussino, K, Wimberger, P, Sehouli, J.
Arch Gynecol Obstet, (2018) 297 (4):837-46.doi:10.1007/s00404-018-4673-0 PMID:29356953
The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
Bushati, M, Rovers, K P, Sommariva, A, Sugarbaker, P H, Morris, D L, Yonemura, Y, Quadros, C A, Somashekhar, S P, Ceelen, W, Dube, P, Li, Y, Verwaal, V J, Glehen, O, Piso, P, Spiliotis, J, Teo, M C C, Gonzalez-Moreno, S, Cashin, P H, Lehmann, K, Deraco, M, Moran, B, de Hingh, I.
Eur J Surg Oncol, (2018) 44 (12):1942-8.doi:10.1016/j.ejso.2018.07.003 PMID:30075978
Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study.
Teixeira Farinha, H, Grass, F, Kefleyesus, A, Achtari, C, Romain, B, Montemurro, M, Demartines, N, Hubner, M.
Gastroenterol Res Pract, (2017) 2017:4596176.doi 10.1155/2017/4596176 PMID:28316621
Major postoperative complications are a risk factor for impaired survival after CRS/HIPEC.
Schneider, M A, Eshmuminov, D, Lehmann, K.
Ann Surg Oncol, (2017) doi: 10.1245/s10434-017-5821-7 PMID:28265776
Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study.
Hubner, M, Teixeira Farinha, H, Grass, F, Wolfer, A, Mathevet, P, Hahnloser, D, Demartines, N.
Gastroenterol Res Pract, (2017) 2017:6852749.doi:10.1155/2017/6852749 PMID:28331493
Pressurized IntraPeritoneal Aerosol Chemotherapy – Practical aspects.
Hubner, M, Grass, F, Teixeira-Farinha, H, Pache, B, Mathevet, P, Demartines, N.
Eur J Surg Oncol, (2017) 43 (6):1102-9.doi: 10.1016/j.ejso.2017.03.019 PMID:28431896
http://www.ncbi.nlm.nih.gov/pubmed/28431896
Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis.
Grass, F, Vuagniaux, A, Teixeira-Farinha, H, Lehmann, K, Demartines, N, Hubner, M.
Br J Surg, (2017) 104 (6):669-78.doi:10.1002/bjs.10521 PMID:28407227
Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review.
El-Nakeep, S, Rashad, N, Oweira, H, Schmidt, J, Helbling, D, Giryes, A, Petrausch, U, Mehrabi, A, Decker, M, Abdel-Rahman, O.
Expert Rev Gastroenterol Hepatol, (2017) 11 (3):249-58.doi:10.1080/17474124.2017.1284586 PMID:28099818
Past events
Symposium 2014
Lectures 2014
n.a.
To become a member
If you perform HIPEC or related procedures or if you are interested in the treatment of PSM or related procedures we would like to invite you to become a member of the group. As a member you can actively participate in the work of the SPCG and will be informed about the current developments and activities of the Group.
Since we are a workgroup of the SGVC, full membership can only be granted to members of the Swiss Society for Visceral Surgery or the Swiss Society for Surgery. Otherwise holders of an FMH-title or an FMH-equivalent title would be eligible for associate membership (“zugewandte Mitgliedschaft”).
If you are interested to become a member of the Swiss Peritoneal Cancer Group please fill out the form linked on register now and send it directly back per e-mail or to Tanja Burkard. Her contact details can be found below.
The membership fee of the Swiss Peritoneal Cancer Group will be included in the invoice for the membership fee of the Swiss Society for Visceral Surgery (SGVC).
Links
Contact details
In case you have any questions please do not hesitate to contact Tanja Burkard who will surely help you with your requests.
Adress
Tanja Burkard
Kantonsspital St. Gallen
Klinik für Allgemein-, Viszeral-, Endokrin- und Transplantationschirurgie
Rorschacherstrasse 95
CH-9007 St. Gallen
E-Mail: tanja.burkard@kssg.ch
Phone: +41 71 494 1344